Screener
Syndax Pharmaceuticals SNDX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 74,843 | 103,064 |
| Current portion of right-of-use liability | 487 | 470 |
| Current portion of capital lease | 1 | 2 |
| Total current liabilities | 86,174 | 120,116 |
| Long-term liabilities: | ||
| Royalty interest financing liability, less current portion | 343,965 | 343,909 |
| Right-of-use liability, less current portion | 907 | 1,051 |
| Total long-term liabilities | 344,872 | 344,960 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's total current liabilities?
- Syndax Pharmaceuticals (SNDX) reported total current liabilities of $86.17M in Q1 2026.
- How has Syndax Pharmaceuticals's total current liabilities changed year-over-year?
- Syndax Pharmaceuticals's total current liabilities decreased by 8.9% year-over-year, from $94.55M to $86.17M.
- What is the long-term trend for Syndax Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's total current liabilities has grown at a 44.8% compound annual growth rate (CAGR), from $18.87M to $120.12M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Syndax Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude